Lilly Shifts Course With Alzheimer’s Drug Solanezumab
This article was originally published in The Pink Sheet Daily
Executive Summary
In another sign of uncertainty for Alzheimer’s disease drug development, Lilly shakes things up with announcement of design changes for Phase III trial for solanezumab.
You may also be interested in...
Lilly Executes Growth Strategy As New Products Drive Sales Gains
Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.
Where Is The Patient Voice In Alzheimer's Disease Drug Development?
Companies focused on Alzheimer's R&D need to catch up on patient involvement, and earlier diagnosis may help, patient advocate suggests.
Standards For Early Alzheimer’s Drugs Adapted, Not Loosened, FDA’s Katz Says
A draft guidance for development of drugs to treat early Alzheimer’s disease does not loosen agency standards, FDA’s neurology products chief asserts. Rather, it is an attempt to establish criteria tailored to the population.